By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. WASHINGTON — The Food and Drug ...

After a tumultuous year, experts call for stability while anticipating the first fruits of policies intended to expedite ...

A top FDA official says next year will be a critical time for the Trump administration to make progress on several of Robert ...

After a long run of regulatory stumbles and the recent withdrawal of its lone commercial drug from the U.S. market, Intercept Pharmaceuticals is implementing a restructuring and rounds of job cuts in ...

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

The medtech market has been hit left and right throughout 2025 with new regulations, uncontrollable changes, and government wide layoffs. As a result, it is nearly impossible to know what job seekers, ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

From nuclear power to immigration to layoffs, here are some attempts to guess the big business stories of the next 12 months.

Catalent’s sweeping workforce reductions within its Maryland gene therapy manufacturing operations were preceded by two FDA inspections in April that resulted in red flags from the agency, FDA filings ...

As 2026 kicks in, we take a quick look back on 2025 – another bearish year for ASX healthcare. Australia’s leading analysts ...